Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.59 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.59 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14465908 | 0.91 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL14165128 | 0.91 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL16573340 | 0.83 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL10140415 | 0.83 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL19156224 | 0.83 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL13615983 | 0.82 | ALDH1A1 (0.55) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL12449153 | 0.82 | ALDH1A1 (0.55) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL5020025 | 0.82 | ALDH1A1 (0.55) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL25146761 | 0.82 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL25146770 | 0.82 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230130516-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-04-27 | — | — | US | disclosed |
| US-20220177577-A1 | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| EP-3888657-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3513793-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10221142-B2 | Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| WO-2018102419-A1 | COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS | Epizyme, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180016239-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-01-18 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2012007493-A1 | PURINE COMPOUNDS SELECTIVE FOR ΡI3Κ P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | SREBF1, SREBF2, XBP1 | CHRNB2 4658/4885CHRNA4 4783/4885CHRNA3 4612/4885 |
| US-20180016239-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORA, RORC | CHRNB2 1695/4885CHRNA4 1721/4885CHRNA3 1192/4885 |
| US-20230130516-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR1, TLR9 | CHRNB2 3264/4885CHRNA4 1981/4885CHRNA3 2250/4885 |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | HDAC10, PDE10A, PDE9A | CHRNB2 1341/4885CHRNA4 1055/4885CHRNA3 821/4885 |
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | AVPR1B, PRLHR, HRH4 | CHRNB2 294/4885CHRNA4 420/4885CHRNA3 497/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | CHRNB2 4542/4885CHRNA4 4546/4885CHRNA3 4435/4885 |
| US-20220177577-A1 | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF | SIGLEC7, FUT7, ITGB7 | CHRNB2 2507/4885CHRNA4 1698/4885CHRNA3 1624/4885 |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | CHRNB2 421/4885CHRNA4 279/4885CHRNA3 299/4885 |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | NFKB1, NFRKB, NFKBIA | CHRNB2 2092/4885CHRNA4 3180/4885CHRNA3 3022/4885 |
| US-10221142-B2 | Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof | RORB, RORA, RORC | CHRNB2 1695/4885CHRNA4 1721/4885CHRNA3 1192/4885 |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | CHRNB2 1834/4885CHRNA4 1427/4885CHRNA3 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.